Long-term follow-up study of patients with adrenal incidentalomas.
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The incidence of adrenal incidentalomas has sharply increased in recent decades and concurrent subtle endocrine abnormalities, or even subclinical conditions, have been identified. Nonetheless, data concerning possible changes in adrenal size and/or hormonal pattern during follow-up are still inadequate. OBJECTIVE: To evaluate long-term morphological and functional evolution of adrenal incidentalomas after initial diagnosis and to identify possible risk factors for hormonal hyperactivity and mass enlargement. PATIENTS: Sixty-four patients (34-79 years) were followed-up for 12-120 months (median 25.5 months). Initial computerized tomography scan showed a unilateral mass in 51 patients and bilateral lesions in 13 patients. Average mass diameter at diagnosis was 2.5+/-0.1 cm (range 1.0-4.0). Twelve patients had subclinical Cushing's syndrome, 41 had mild hormonal alterations, and 11 had normal adrenal function at baseline. All patients were investigated by morphological and functional evaluation 6 and 12 months after diagnosis, and then at 1-year intervals. RESULTS: During follow-up, a mass size increase >/=1 cm was observed in 13 patients, and 18 developed further subtle endocrine alterations. Cumulative risk of developing endocrine abnormalities was 17% at 1 year, 29% at 2 years, and 47% at 5 years. The risk was higher in the first 2 years of follow-up if the initial tumor diameter was >or=3 cm. Overall, cumulative risk of mass enlargement was 6% at 1 year, 14% at 2 years, and 29% at 5 years, and it was greater in patients with normal adrenal function than in those with subtle hormonal abnormalities (P<0.05). One female subject showed a mass enlargement after 6 months of follow-up and was eventually diagnosed with non-Hodgkin's lymphoma. CONCLUSIONS: Patients with an adrenal incidentaloma are at risk for tumor growth and development of hormonal alterations. The risk of adrenal malignancy, although not elevated, also indicates the need for long-term follow-up.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bulow et al. (31) reported 2% prevalence of Cushing's syndrome; Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
From The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. (2008) · cites this paper as [32]
In the citing paper
“However, if the lowest cutoffs were used [1.8 and 2.2 g/dl (50 and 60.6 nmol/liter), respectively], specificity decreased to 67-72%, whereas sensitivity increased to 75-100% (48 -62, 64 -67).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
In the citing paper
“Overall, in these studies, the different parameters showed a good specificity (90 -98%, using 1-mg DST) but, generally, a poor sensitivity (41-86% using ACTH levels).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
In the citing paper
“two studies suggested that in patients with an adrenal mass more than 2 cm in size, the estimated cumulative risk of developing SH may vary between 7 and 47% after 5 yr (50,52).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
Citations
Cites
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 855
Incidentally Discovered Adrenal Masses*
KLOOS, R. T., GROSS, M. D., FRANCIS, I. R., KOROBKIN, M., & SHAPIRO, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-460 · Cited by 828
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Reincke, M. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.3.826 · Cited by 348 · cited 1×
“As previously reported (6, 9, 10 ), SCS was defined by the absence of signs or symptoms of hypercortisolism and by the presence of at least two of the following criteria: inadequate cortisol inhibition after 1 mg dexamethasone (cortisol levels $ 138 nmol/l), high or high – normal UFC excretion ($ 275 nmol/24 h), low o…”
BackgroundInfluentialSubclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285
Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1
Barzon, L., Scaroni, C., Sonino, N., Fallo, F., Paoletta, A., & Boscaro, M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5444 · Cited by 254 · cited 1×
“Recently, Barzon et al. (14) evaluated long-term clinical, hormonal, and morphological outcomes in patients with adrenal incidentalomas in order to obtain prognostic factors for disease progression. European Journal of Endocrinology (2002) 147 489–494 ISSN 0804-4643”
BackgroundSerendipitous adrenal masses: Prevalence, significance, and management
Abecassls, M., McLoughlin, M. J., Langer, B., & Kudlow, J. E. (1985) · The American Journal of Surgery · doi:10.1016/s0002-9610(85)80186-0 · Cited by 233
Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas)
Osella, G., Terzolo, M., Borretta, G., Magro, G., Alí, A., Piovesan, A., Paccotti, P., & Angeli, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989452 · Cited by 206
Subclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo, Osella, Alì, Borretta, Cesario, Paccotti, & Angeli, A. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00357.x · Cited by 198 · cited 1×
“However, in our retrospective study no patient showed an evolution to overt clinical hypercortisolism, in agreement with previous reports ( 11 , 15).”
ResultAbnormalities of endocrine function in patients with clinically silent adrenal masses.
Ambrosi, B., Peverelli, S., Passini, E., Re, T., Ferrario, R., Colombo, P., Sartorio, A., & Faglia, G. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1320422 · Cited by 136 · cited 2×
“As previously reported ( 6 , 9, 10), SCS was defined by the absence of signs or symptoms of hypercortisolism and by the presence of at least two of the following criteria: inadequate cortisol inhibition after 1 mg dexamethasone (cortisol levels $ 138 nmol/l), high or high – normal UFC excretion ($ 275 nmol/24 h), low…”
BackgroundMethodInfluentialSelf-citation
Cited by
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
The Incidentally Discovered Adrenal Mass
Young, W. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp065470 · Cited by 1,096
Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“large and 3–4% may decrease in size (57, 63, 202, 467).”
Prevalence and natural history of adrenal incidentalomas
Barzon, L., Sonino, N., Fallo, F., Palu, G., & Boscaro, M. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490273 · Cited by 642
“Our results have been confirmed by Libe ` et al. ( 108 ) who demonstrated that mass size greater than 3 cm and endocrine abnormalities at diagnosis were risk factors for adrenal hyperfunction and mass enlargement respectively.”
BackgroundResultAME Position Statement on adrenal incidentaloma
Terzolo, M., Stigliano, A., Chiodini, I., Loli, P., Furlani, L., Arnaldi, G., Reimondo, G., Pia, A., Toscano, V, Zini, M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1147 · Cited by 520
“Different authors have used a number of criteria, often including a pair of altered test results (9, 13, 102, 104, 110, 116, 118, 119).”
InfluentialZeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
“Several investigators have shown that elevated nighttime cortisol levels appear to be the earliest and most sensitive markers for Cushing syndrome (24 [EL 4], 25 [EL 4]), with sensitivity and specificity approaching 90% to 95% (26 [EL 3]) .”
InfluentialCawood, T. J., Hunt, P. J., O'Shea, D., Cole, D., & Soule, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0234 · Cited by 300
“Cushing’s syndrome is lower than that found in other studies (92% ( 45 ), 100% (40), 86% (52) and 83% (53)), although these other studies were much smaller (6–12 patients, compared with 92 (30)).”
BackgroundResultDiagnosis and Treatment of Subclinical Hypercortisolism
Chiodini, I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2722 · Cited by 279
“Mantero, 2000 (9) 1004 43/83 79/85 76/88 73/90 1 mg, 5 g/dl 2 out of CRH, CCR, ACTH, UFC, DST Libè 2002 (52) 64 n.”
MethodHamrahian, A. H., Ioachimescu, A. G., Remer, E. M., Motta-Ramirez, G., Bogabathina, H., Levin, H. S., Reddy, S., Gill, I. S., Siperstein, A., & Bravo, E. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1627 · Cited by 266
“On the other hand, follow-up of patients with nonfunctioning adrenal masses suggests that 5–25% of adrenal masses increase in size by at least 1 cm (30, 57, 58).”
BackgroundElhassan, Y. S., Alahdab, F., Prete, A., Delivanis, D. A., Khanna, A., Prokop, L., Murad, M. H., O'Reilly, M. W., Arlt, W., & Bancos, I. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3630 · Cited by 263
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study
Morelli, V., Reimondo, G., Giordano, R., Della Casa, S., Policola, C., Palmieri, S., Salcuni, A. S., Dolci, A., Mendola, M., Arosio, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3527 · Cited by 223
“In accordance with some (7, 27) but not all (15, 16) authors in our series, no patients showed a normalization of the adrenal function.”
Self-citationChiodini, I., Torlontano, M., Scillitani, A., Arosio, M., Bacci, S., Di Lembo, S., Epaminonda, P., Augello, G., Enrini, R., Ambrosi, B., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02045 · Cited by 190
Self-citationDi Dalmazi, G., Vicennati, V., Rinaldi, E., Morselli-Labate, A. M., Giampalma, E., Mosconi, C., Pagotto, U., & Pasquali, R. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1039 · Cited by 184
Subclinical Cushing’s syndrome in adrenal incidentalomas
Terzolo, M., Bovio, S., Reimondo, G., Pia, A., Osella, G., Borretta, G., & Angeli, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.008 · Cited by 179
“Masses of 3 cm or greater are more likely to develop silent hyperfunction than smaller tumors, and the risk seems to plateau after 3 to 4 years, even if it does not subside completely [75,82].”
BackgroundAdrenal myelolipoma: a comprehensive review
Decmann, Á., Perge, P., Tóth, M., & Igaz, P. (2017) · Endocrine · doi:10.1007/s12020-017-1473-4 · Cited by 154
“Regarding adrenocortical adenomas, the European Society of Endocrinology’s latest guideline proposes that if an incidentaloma is homogenous, its imaging features are consistent with a benign adrenal mass (<10 HU) and smaller than 4 cm in diameter, no further imaging is needed [55, 59, 60].”
BackgroundClinical guidelines for the management of adrenal incidentaloma
Lee, J.-M., Kim, M. K., Ko, S.-H., Koh, J.-M., Kim, B.-Y., Kim, S. W., Kim, S.-K., Kim, H. J., Ryu, O.-H., Park, J., et al. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.200 · Cited by 147
Guidelines for the management of the incidentally discovered adrenal mass
Kapoor, A., Morris, T., & Rebello, R. (2011) · Canadian Urological Association Journal · doi:10.5489/cuaj.11135 · Cited by 140
Medical and Surgical Evaluation and Treatment of Adrenal Incidentalomas
Zeiger, M. A., Siegelman, S. S., & Hamrahian, A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0085 · Cited by 135
“Until data from large prospective studies are available, annual biochemical follow-up for up to 5 yr may be reasonable for patients with adrenal incidentalomas, especially if the tumor is more than 3 cm in size (20, 21, 37, 45).”
BackgroundMethodSubclinical Cushing’s syndrome: definition and management
Terzolo, M., Pia, A., & Reimondo, G. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04253.x · Cited by 130
Exploration and management of adrenal incidentalomas.
Tabarin, A., Bardet, S., Bertherat, J. Y., Dupas, B., Chabre, O., Hamoir, E., Laurent, F., Tenenbaum, F., Cazalda, M., Lefèbvre, H., et al. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.09.003 · Cited by 148
Adrenal incidentaloma—follow-up results from a Swedish prospective study.
Bülow, B., Jansson, S., Juhlin, C., Steen, L., Thorén, M., Wahrenberg, H., Valdemarsson, S., Wängberg, B., Ahréen, B., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02110 · Cited by 124
“The higher percentage of tumour growth in some previous reports might be explained by a longer follow-up period ( 13 , 16, 17), as the cumulative risk of mass enlargement seems to increase with time (17).”
BackgroundResultMatyakhina, L., Freedman, R. J., Bourdeau, I., Wei, M.-H., Stergiopoulos, S. G., Chidakel, A., Walther, M., Abu-Asab, M., Tsokos, M., Keil, M., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2377 · Cited by 114
Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications.
Tsagarakis, S., Vassiliadi, D., & Thalassinos, N. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344133 · Cited by 113
Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study
Vassilatou, E., Vryonidou, A., Michalopoulou, S., Manolis, J., Caratzas, J., Phenekos, C., & Tzavara, I. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03492.x · Cited by 112
Patrova, J., Kjellman, M., Wahrenberg, H., & Falhammar, H. (2017) · Endocrine · doi:10.1007/s12020-017-1400-8 · Cited by 117
Laparoscopic adrenalectomy—indications and technique
Lal, G., & Duh, Q. (2003) · Surgical Oncology · doi:10.1016/s0960-7404(03)00036-7 · Cited by 113
“[63] Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B.”
BackgroundGiordano, R., Marinazzo, E., Berardelli, R., Picu, A., Maccario, M., Ghigo, E., & Arvat, E. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0957 · Cited by 99
TSUIKI, M., TANABE, A., TAKAGI, S., NARUSE, M., & TAKANO, K. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07e-177 · Cited by 97
“Although not common [21, 22], cases of subclinical Cushing’s syndrome developing into overt Cushing’s syndrome have been reported in the literature [23, 24].”
BackgroundThe diagnosis of Cushing’s syndrome
Carroll, T. B., & Findling, J. W. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9143-3 · Cited by 108
Peppa, Μ., Boutati, E. I., Koliaki, C. C., Papaefstathiou, N., Garoflos, E., Economopoulos, T., Hadjidakis, D., & Raptis, S. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.007 · Cited by 102
“The risk was higher in the first 2 years of follow-up if the initial tumor diameter was at least 3 cm [28].”
BackgroundInfluentialBernini, G. P., Moretti, A., Oriandini, C., Bardini, M., Taurino, C., & Salvetti, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602459 · Cited by 87
“…size have been reported in adrenal incidentalomas (Bastounis et al, 1997; Barry et al, 1998; Terzolo et al, 1998; Barzon et al, 1999; Siren et al, 2000; Libe et al, 2002; Grumbach et al, 2003), with such variations sometimes believed to reflect a more aggressive growth rate (Mansmann et al, 2004).”
BackgroundAnsquer, C., Scigliano, S., Mirallié, É., Taïeb, D., Brunaud, L., Sebag, F. A., Leux, C., Drui, D., Dupas, B., Renaudin, K., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1471-8 · Cited by 86
“Then, it is widely accepted that surgery should be discussed in patients who have lesions with radiological features suggesting malignancy or showing hormonal hypersecretion, whereas patients with non-secreting lesions and radiological features suggesting benignity should undergo biochemical and imaging follow-up [2,…”
BackgroundSereg, M., Szappanos, Á., Tőke, J., Karlinger, K., Feldman, K., Kaszper, É., Varga, I., Gláz, E., Rácz, K., & Tóth, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0707 · Cited by 81
Subclinical Cushing's syndrome.
Terzolo, M., Reimondo, G., Bovio, S., & Angeli, A. (2004) · Pituitary · doi:10.1007/s11102-005-4024-6 · Cited by 80
Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism
Tauchmanovà, L., Pivonello, R., De Martino, M. C., Rusciano, A., De Leo, M., Ruosi, C., Mainolfi, C., Lombardi, G., Salvatore, M., & Colao, A. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0137 · Cited by 80
“Greater bone loss was also found in women on replacement therapy for 21-hydroxylase deficit and lower androgen levels ( 34 ), supporting the hypothesis on the importance of cortisol-to-androgen ratio in BMD maintenance (8, 32, 35).”
Adrenal incidentaloma: a diagnostic challenge
Anagnostis, P. G., Karagiannis, A. I., Τζιόμαλος, Κ., Kakafika, A. I., Athyros, V. G., & Mikhailidis, D. P. (2009) · HORMONES · doi:10.14310/horm.2002.1233 · Cited by 96
Autonomous cortisol secretion in adrenal incidentalomas
Castro, M. A., Núñez, M. A. S., & Marazuela, M. (2019) · Endocrine · doi:10.1007/s12020-019-01888-y · Cited by 87
Aron, D. C., Terzolo, M., & Cawood, T. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.06.012 · Cited by 83
Hong, A. R., Kim, J. H., Park, K. S., Kim, K. Y., Lee, J. H., Kong, S. H., Lee, S. Y., Shin, C. S., Kim, S. W., & Kim, S. Y. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0372 · Cited by 74
Subclinical Cushing's syndrome in adrenal incidentalomas
Sippel, R. S., & Chen, H. (2004) · Surgical Clinics of North America · doi:10.1016/j.suc.2004.01.001 · Cited by 75
“Libe and associates [22] prospectively followed 12 patients with SCS, with a median follow-up of 25.”
BackgroundAdrenal incidentaloma: evaluation and management
Singh, P. K., & Buch, H. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.044313 · Cited by 80
Change in Adrenal Mass Size as a Predictor of a Malignant Tumor
Pantalone, K. M., Gopan, T., Remer, E. M., Faiman, C., Ioachimescu, A. G., Levin, H. S., SIPERSTEIN, A. E., Berber, E., Shepardson, L. B., Bravo, E. L., et al. (2010) · Endocrine Practice · doi:10.4158/ep09351.or · Cited by 71
Subclinical Cushing's syndrome
Terzolo, M., Bovio, S., Pia, A., Osella, G., Borretta, G., Angeli, A., & Reimondo, G. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800013 · Cited by 69
“Adrenal adenomas of 3 cm or greater are more likely to develop silent hyperfunction than smaller tumors and the risk seems to plateau after 3 to 4 years, even if it does not completely subside [16, 53 ].”
BackgroundSubclinical Cushing’s syndrome
Leo, M. D., Cozzolino, A., Colao, A. A. L., & Pivonello, R. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.02.001 · Cited by 71
Clinical Study of Adrenal Incidentaloma in Korea
Kim, H. Y., Kim, S. G., Lee, K. W., Seo, J. A., Kim, N. H., Choi, K. M., Baik, S. H., & Choi, D. S. (2005) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2005.20.4.303 · Cited by 62
The clinical significance of adrenal incidentalomas
Androulakis, I. I., Kaltsas, G., Piaditis, G., & Grossman, A. B. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02436.x · Cited by 61
Fagour, C., Bardet, S., Rohmer, V., Arimone, Y., Lecomte, P., Valli, N., & Tabarin, A. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0299 · Cited by 59
Pros and cons of screening for occult Cushing syndrome
Tabarin, A., & Perez, P. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.51 · Cited by 57
Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas
Cho, Y. Y., Suh, S., Joung, J. Y., Jeong, H., Je, D., Yoo, H., Park, T. K., Min, Y.-K., Kim, K.-W., & Kim, J. H. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.5.557 · Cited by 56
“Several studies demonstrated that tumor size greater than 3 cm at diagnosis was related to the occurrence of hormonal hyperfunction [25,32].”
BackgroundCT-scan, MRI and image-guided FNA cytology of incidental adrenal masses
Lumachi, F., Borsato, S., Tregnaghi, A., Basso, S. M. M., Marchesi, P., Ciarleglio, F. A., Fassina, A., & Favia, G. (2003) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(03)00159-8 · Cited by 59
Adrenal incidentalomas — a continuing management dilemma
Nawar, R., & Aron, D. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00951 · Cited by 55
“About 5–25% increase in size by at least 1 cm and 3–4% decrease (Jockenhovel et al. 1992, Kasperlik-Zeluska et al. 1997, Barzon et al. 1999, 2002, Siren et al. 2000, Grossrubatscher et al. 2001, Lau et al. 2002, Libe et al. 2002).”
BackgroundPrevalence of Functioning Adrenal Incidentalomas: A Systematic Review and Meta-analysis
Sconfienza, E., Tetti, M., Forestiero, V., Veglio, F., Mulatero, P., & Monticone, S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad044 · Cited by 61
Differences in Growth Rate on CT of Adrenal Adenomas and Malignant Adrenal Nodules
Corwin, M. T., Navarro, S. M., Malik, D. G., Loehfelm, T. W., Fananapazir, G., Wilson, M., & Campbell, M. J. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.19.21342 · Cited by 50
Papanastasiou, L., Alexandraki, K., Androulakis, I. I., Fountoulakis, S., Kounadi, T., Markou, Α., Tsiavos, V., Samara, C., Papaioannou, T., Piaditis, G. P., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13294 · Cited by 55
Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment.
Mazzuco, T. L., Bourdeau, I., & Lacroix, A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832b7043 · Cited by 48
Park, J., De Luca, A., Dutton, H., Malcolm, J. C., & Doyle, M.-A. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00090 · Cited by 46
Shen, J., Sun, M., Zhou, B., & Yan, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0345 · Cited by 44
Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists?
Sahdev, A. (2017) · British Journal of Radiology · doi:10.1259/bjr.20160627 · Cited by 44
Castro, M. A., Lázaro, C. R., Ramírez, P. A. P., Hernández, M. C., Núñez, M. A. S., & Marazuela, M. (2019) · Endocrine · doi:10.1007/s12020-019-02066-w · Cited by 51
Castro, M. A., Guevara, M. I., Gutiérrez, M. C., Ramírez, P. A. P., Gimeno, P. G., Hanzu, F. A., & Lamas, C. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.03.002 · Cited by 50
cAMP signaling in cortisol-producing adrenal adenoma
Calebiro, D., Di Dalmazi, G., Bathon, K., Ronchi, C. L., & Beuschlein, F. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0353 · Cited by 45
Clinical Features of 50 Patients With Primary Adrenal Lymphoma
Wang, Y., Ren, Y., Li-fen, M., Li, J., Zhu, Y., Zhao, L., Tian, H., & Chen, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00595 · Cited by 46
“First, despite the absence of benign characteristics, a PAL on CT and/or magnetic resonance imaging (MRI) may lead to misdiagnosis in the initial evaluation (4); furthermore in some cases, PAL is difficult to distinguish from adrenocortical carcinoma (ACC) (5) and pheochromocytoma (6).”
BackgroundTsvetov, G., Shimon, I., & Benbassat, C. A. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03347444 · Cited by 42
Adrenal incidentalomas: Risk of adrenocortical carcinoma and clinical outcomes
O’Neill, C. J., Spence, A., Logan, B., Suliburk, J. W., Soon, P. S. H., Learoyd, D., Sidhu, S. B., & Sywak, M. S. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21553 · Cited by 42
“16–47% of patients will develop endocrine abnormalities (subclinical Cushing’s syndrome being most common) and 9–29% of lesions will enlarge by more than 1 cm [7,14].”
BackgroundProspective evaluation of tumor size and hormonal status in adrenal incidentalomas
Yener, S., Ertilav, S., Seçil, M., Demir, T., Akıncı, B., Kebapçılar, L., Comlekci, A., Bayraktar, F., & Yeşil, S. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346546 · Cited by 45
Adrenal Incidentalomas: Clinical Controversies and Modified Recommendations
Garrett, R. W., Nepute, J., Hayek, M. E., & Albert, S. G. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15475 · Cited by 42
“This view is contrary to the preponderance of clinical recommendations in the endocrine literature [4, 5, 33, 36, 37, 40].”
BackgroundResultLumachi, F., Borsato, S., Tregnaghi, A., Marino, F., Fassina, A., Zucchetta, P., Marzola, M. C., Cecchin, D., Bui, F., Iacobone, M., et al. (2007) · Tumori Journal · doi:10.1177/030089160709300307 · Cited by 39
Adrenocortical tumors and insulin resistance: What is the first step?
Altieri, B., Tirabassi, G., Casa, S. D., Ronchi, C. L., Balercia, G., Orio, F., Pontecorvi, A., Colao, A., & Muscogiuri, G. (2015) · International Journal of Cancer · doi:10.1002/ijc.29950 · Cited by 40
“Indeed, some reports supported this hypothesis, although other authors did not find a statistically significant difference between SCS and non-functioning tumors.(116,117) Several studies evaluated the potential effect of chronic hyperinsulinemia on adrenal tumor growth in patients with T2DM.”
ResultClinical Characteristics and Follow-Up Results of Adrenal Incidentaloma
Yılmaz, N., Avşar, E., Tazegül, G., Sarı, R., Altunbaş, H., & Balcı, M. K. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1079-4915 · Cited by 43
Echocardiographic alterations in patients with non-functioning adrenal incidentaloma
Ermetici, F., Dall’Asta, C., Malavazos, A. E., Coman, C., Morricone, L. F., Montericcio, V., & Ambrosi, B. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346410 · Cited by 36
Self-citationMorelli, V., Scillitani, A., Arosio, M., & Chiodini, I. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0558-x · Cited by 40
“Figure 1 summarized the available data regarding the risk of SH development over time [8–20].”
BackgroundPetramala, L., Cavallaro, G., Galassi, M., Marinelli, C., Tonnarini, G., Concistrè, A., Costi, U., Bufi, M., Lucia, P., VINCENTIS, G. D., et al. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0182-7 · Cited by 34
“[27] none of 12 patients with SH developed overt CS during 25.”
BackgroundAssessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses
Yozamp, N., & Vaidya, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101491 · Cited by 33
Subclinical Cushing’s syndrome: Current concepts and trends
Zografos, G. N., Perysinakis, I., & Vassilatou, E. (2014) · HORMONES · doi:10.14310/horm.2002.1506 · Cited by 35
Management of adrenal incidentaloma: the role of adrenalectomy may be underestimated
Ye, Y., Yuan, X., Chen, M., Dai, Y., Qin, Z., & Zheng, F. (2016) · BMC Surgery · doi:10.1186/s12893-016-0154-1 · Cited by 40
Adrenal incidentalomas: Experience from a retrospective study in a Chinese population
Xu, B., Yang, Q., Linhui, W., Gao, L., & Yinghao, S. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.03.027 · Cited by 33
Incidentally Discovered Adrenal Mass
Song, J. H., & Mayo-Smith, W. W. (2010) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2010.10.006 · Cited by 34
Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders
Kutikov, A., Crispen, P. L., & Uzzo, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00057-8 · Cited by 34
Adrenal Incidentalomas: Diagnostic Evaluation and Long-Term Follow-Up
Vilar, L., Freitas, M., Canadas, V., Albuquerque, J., Botelho, C., Egito, C. S., Arruda, M., Silva, L. M. E., Coelho, C., Casulari, L. A., et al. (2008) · Endocrine Practice · doi:10.4158/ep.14.3.269 · Cited by 29
A multidisciplinary approach to the management of adrenal incidentaloma
Voltan, G., Boscaro, M., Armanini, D., Scaroni, C. M., & Ceccato, F. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1948327 · Cited by 30
Yeomans, H., Calissendorff, J., Volpe, C., Falhammar, H., & Mannheimer, B. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0001-x · Cited by 26
“In contrast, other studies have indicated a potential of hormonal activation in patients with an initial negative screening and therefore support longterm hormonal monitoring [14-16].”
ResultCurrent status and controversies in adrenal incidentalomas
Kaltsas, G., Chrisoulidou, A., Piaditis, G. P., Kassi, E. N., & Chrousos, G. P. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.09.001 · Cited by 27
Reimondo, G., Allasino, B., Bovio, S., Saba, L., Ardito, A., Angeli, A., & Terzolo, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346701 · Cited by 32
Falcetta, P., Orsolini, F., Benelli, E., Agretti, P., Vitti, P., Cosmo, C. D., & Tonacchera, M. (2020) · Endocrine · doi:10.1007/s12020-020-02476-1 · Cited by 30
Khadembashiri, M. M., Mohseni, S., Harandi, H., Sani, M. P., Khadembashiri, M. A., Atlasi, R., SeyedAlinaghi, S., Mohajeri‐Tehrani, M. R., & Larijani, B. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1374711 · Cited by 28
“Additional research has also demonstrated that the progression from MACS to Overt Cushing ’ s syndrome is infrequent (96 – 98).”
BackgroundIs Follow-up of Adrenal Incidentalomas Always Mandatory?
Reimondo, G., Muller, A., Ingargiola, E., Puglisi, S., & Terzolo, M. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.26 · Cited by 26
Castro, M. A., Guevara, M. I., Gutiérrez, M. C., Ramírez, P. A. P., Gimeno, P. G., Hanzu, F. A., & Lamas, C. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.08.010 · Cited by 27
Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation.
Tirabassi, G., Kola, B., Ferretti, M., Papa, R., Mancini, T., Mantero, F., Scarpelli, M., Boscaro, M., & Arnaldi, G. (2012) · PubMed · doi:10.3275/8010 · Cited by 22
Management of the Incidental Adrenal Mass
Thomas, A. Z., Blute, M. L., Seitz, C., Habra, M. A., & Karam, J. A. (2016) · European Urology Focus · doi:10.1016/j.euf.2015.12.006 · Cited by 22
“When participants were divided by mass size at diagnosis, the risk of further endocrine changes in the first 2 yr of follow-up was higher in patients with adrenal lesions >3 versus <3 cm [46].”
BackgroundPrecursor Lesions of the Adrenal Gland
van Nederveen, F. H., & de Krijger, R. R. (2007) · Pathobiology · doi:10.1159/000105811 · Cited by 24
WFUMB position paper on the management incidental findings: adrenal incidentaloma
Dietrich, C. F., Correas, J. M., Dong, Y., Nolsøe, C., Westerway, S. C., & Jenssen, C. (2019) · ULTRASONOGRAPHY · doi:10.14366/usg.19029 · Cited by 23
“Autonomous glucocorticoid function may also develop over time; therefore, follow-up testing should be considered [33,36,84,85].”
BackgroundBeltsevich, D. G., Mel'nichenko, G. A., Kuznetsov, N. S., Troshina, E. A., Platonova, N. M., Vanushko, V. E., Yukina, M. Y., & Молашенко, Н. В. (2016) · Endocrine Surgery · doi:10.14341/serg2016431-42 · Cited by 24
Starker, L. F., Kunstman, J. W., & Carling, T. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.02.008 · Cited by 25
Incidental and Metastatic Adrenal Masses
Mannelli, M., Colagrande, S., Valeri, A., & Parenti, G. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.018 · Cited by 23
Hormonal activity in clinically silent adrenal incidentalomas
Babińska, A., Siekierska-Hellmann, M., Błaut, K., Lewczuk, A., Wiśniewski, P., Gnacińska, M., Obołończyk, Ł., Świątkowska−Stodulska, R., & Sworczak, K. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.27288 · Cited by 22
“At the same time, a gradual increase in hormonal activity, even in the absence of recognized criteria for CS, can be a sign of progression towards this condition [20].”
BackgroundEvaluation and management of pituitary incidentalomas—revisiting an acquaintance
Krikorian, A., & Aron, D. C. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0122 · Cited by 21
“Few studies have looked at the rate of progression of subclinical Cushing syndrome into overt Cushing syndrome and they have yielded conflicting results”
ResultHealth-related quality of life and fatigue in patients with adrenal incidentaloma
Kaštelan, D., Džubur, F., Dušek, T., Poljičanin, T., Crnčević-Orlić, Ž., Kraljević, I., Solak, M., Bencevic, T., Aganović, I., Knežević, N., et al. (2011) · Endocrine · doi:10.1007/s12020-011-9456-3 · Cited by 21
Ferreira, E. V., Czepielewski, M. A., Faccin, C. S., Accordi, M. C., & Furtado, Á. P. A. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000500017 · Cited by 22
Metadata
- Authors
- Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B.
- Affiliations
- University of Milan (IT)
- National Institutes of Health (US)
- Corresponding author
- Ambrosi, B
- ORCID
- Baccarelli, A
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10-01
- Volume
- 147
- Issue
- 4
- Pages
- 489-494
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2134170847
- Cited by
- 215
- References
- 21
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 13 · 2019: 14 · 2018: 7 · 2017: 11 · 2016: 10 · 2015: 11 · 2014: 13 · 2013: 5 · 2012: 14
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- adrenal incidentaloma, subclinical Cushing's syndrome, adrenal hyperfunction, tumor growth, long-term follow-up, risk factors, adrenal function, adrenal malignancy, non-Hodgkin lymphoma
- MeSH terms
- Adrenal Gland Neoplasms, Adult, Aged, Cushing Syndrome, Dexamethasone, Female, Follow-Up Studies, Glucocorticoids, Humans, Hydrocortisone, Male, Middle Aged, Retrospective Studies, Risk Factors, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.